Caredx Inc Cmn (CDNA) 3.76 $CDNA
CareDx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Sep 21, 8:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of its public offering of 2.25 million shares of its common stock at a price to the public of $4.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 337,500 additional shares of its common stock. All of the shares will be offered and sold by CareDx.
CDNA: 3.76 (-0.06)
CareDx Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Sep 20, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. CareDx also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx.
CDNA: 3.76 (-0.06)
CareDx Reports Status of Form 10-Q
GlobeNewswire - Tue Aug 16, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it filed with the Securities and Exchange Commission (SEC) a Form 12b-25 for an extension of time for the filing of its Quarterly Report on Form 10-Q. The Company requested the extension because it needs additional time to complete the final review of its financial statements and other disclosures in the Form 10-Q, namely in light of the Company's recent acquisition of Allenex AB and the requirement to include Allenex AB's results in the Company's consolidated financial statements for the first time. Pursuant to SEC regulations, the Company has until Monday, August 22, 2016 to timely file its Form 10-Q, and the Company anticipates that it will file its Form 10-Q by that date. However, because the review is ongoing, no assurances can be given as to the definitive date on which the Form 10-Q will be filed.
CDNA: 3.76 (-0.06)
CareDx Reports Preliminary Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the second quarter ended June 30, 2016.
CDNA: 3.76 (-0.06)
Healthcare Stocks' Q2 Earnings on Aug 10: QHC, CDNA & CGIX
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 6:52AM CDT
Here, we take a look at three healthcare stocks scheduled to report their second-quarter figures on Aug 10.
CDNA: 3.76 (-0.06), QHC: 6.28 (+0.03), CGIX: 1.76 (-0.06)
CareDx Presents Validation of AlloSure(R) at AACC Conference Session on Emerging Topics in Laboratory Medicine
GlobeNewswire - Thu Aug 04, 3:58PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, presented on the analytical validation of AlloSure at the 68 American Conference on Clinical Chemistry (AACC) in Philadelphia, PA. The CareDx abstract at AACC was one of 22 selected for an oral presentation from over 800 submitted abstracts.
CDNA: 3.76 (-0.06)
Teladoc (TDOC) Q2 Loss Narrower Than Expected, Gives View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 10:04AM CDT
Teladoc (TDOC) incurred loss in the quarter due to an increase in cost of advertising in its direct-to-consumer segment.
TDOC: 18.64 (-0.31), ABCO: 43.58 (-0.60), CDNA: 3.76 (-0.06), AHS: 33.20 (-1.38)
CareDx Supports FDA Development of Next Generation Sequencing Guidelines, Offers Further Perspective on Clinical Grade Quality and Data
GlobeNewswire - Mon Aug 01, 3:05PM CDT
CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, commends the FDA on the release of two draft guidance documents on the standards and the use of public databases for variant detection for Next Generation Sequencing (NGS). Both documents were further supported through a hosted webinar on July 27.
CDNA: 3.76 (-0.06)
CareDx to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 10, 2016
GlobeNewswire - Mon Aug 01, 3:02PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the second quarter 2016 after the market closes on Wednesday, August 10, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
CDNA: 3.76 (-0.06)
AlloSure(TM) Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
GlobeNewswire - Mon Jun 13, 6:30AM CDT
CareDx at the Forefront of Personalized Medicine in Transplantation
CDNA: 3.76 (-0.06)
CareDx (CDNA) Looks Good: Stock Adds 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 7:40AM CDT
CareDx, Inc. (CDNA) saw its shares almost 6% in the last trading session.
AIRM: 32.45 (-0.68), CDNA: 3.76 (-0.06)
CareDx to Host Call to Provide First Analysis of Data from DART Study
GlobeNewswire - Mon Jun 06, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will host a conference call on June 13, 2016 at 4:00 pm ET to provide initial results from the company's DART study.
CDNA: 3.76 (-0.06)
CareDx to Present at 2016 Jefferies Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, CareDx President & Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be presenting and available for meetings at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 4:30pm ET.
CDNA: 3.76 (-0.06)
CareDx and QIAGEN Enter Into Commercial Collaboration to Enhance HLA Lab Experience Using QIAxcel Instrumentation and CareDx HLA Typing Technology
GlobeNewswire - Tue May 31, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced it has signed a memorandum of understanding to collaborate with QIAGEN, the leading provider of Sample to Insight solutions for the life sciences and diagnostics industry.
CDNA: 3.76 (-0.06)
CareDx Announces Completion of Enrollment in Multicenter Kidney Transplant Study to Validate Cell-Free DNA Technology
GlobeNewswire - Fri May 27, 3:05PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that the DART study has reached its enrollment goal.
CDNA: 3.76 (-0.06)
CareDx, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Fri May 06, 6:30AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2016.
CDNA: 3.76 (-0.06)
CareDx to Present Clinical Abstracts Containing New Data at the 2016 ISHLT On AlloMap(R) & AlloSure(TM) in heart transplant patients
GlobeNewswire - Thu Apr 28, 3:52PM CDT
CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced clinical presentations for the 36 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) being held April 27 - 30, 2016 in Washington, DC.
CDNA: 3.76 (-0.06)
CareDx to Announce First Quarter 2016 Financial Results and Host Conference Call on May 6, 2016
GlobeNewswire - Tue Apr 26, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the first quarter 2016 before the market opens on Friday, May 6, 2016. The Company will host a corresponding conference call beginning at 5:30am PT/8:30am ET.
CDNA: 3.76 (-0.06)
CareDx Completes Allenex Acquisition
GlobeNewswire - Thu Apr 14, 3:15PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the completion of its previously announced acquisition of Allenex AB.
CDNA: 3.76 (-0.06)
CareDx Announces $22 Million Private Placement
GlobeNewswire - Thu Apr 14, 3:14PM CDT
CareDx, Inc. (NASDAQ:CDNA) ("CareDx" or the "Company"
, a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced that it has entered into an agreement to sell approximately 592,000 units in a private placement to be issued by CareDx, for aggregate proceeds in the amount of approximately $14.1 million plus an additional $8 million to be reserved for future investment by certain shareholders. The units were sold to selected institutional and accredited investors and included new shareholders as well as significant participation by current shareholders of CareDx.
CDNA: 3.76 (-0.06)
CareDx Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Sep 21, 8:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of its public offering of 2.25 million shares of its common stock at a price to the public of $4.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 337,500 additional shares of its common stock. All of the shares will be offered and sold by CareDx.
CDNA: 3.76 (-0.06)
CareDx Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Sep 20, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. CareDx also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx.
CDNA: 3.76 (-0.06)
CareDx Reports Status of Form 10-Q
GlobeNewswire - Tue Aug 16, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it filed with the Securities and Exchange Commission (SEC) a Form 12b-25 for an extension of time for the filing of its Quarterly Report on Form 10-Q. The Company requested the extension because it needs additional time to complete the final review of its financial statements and other disclosures in the Form 10-Q, namely in light of the Company's recent acquisition of Allenex AB and the requirement to include Allenex AB's results in the Company's consolidated financial statements for the first time. Pursuant to SEC regulations, the Company has until Monday, August 22, 2016 to timely file its Form 10-Q, and the Company anticipates that it will file its Form 10-Q by that date. However, because the review is ongoing, no assurances can be given as to the definitive date on which the Form 10-Q will be filed.
CDNA: 3.76 (-0.06)
CareDx Reports Preliminary Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the second quarter ended June 30, 2016.
CDNA: 3.76 (-0.06)
Healthcare Stocks' Q2 Earnings on Aug 10: QHC, CDNA & CGIX
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 6:52AM CDT
Here, we take a look at three healthcare stocks scheduled to report their second-quarter figures on Aug 10.
CDNA: 3.76 (-0.06), QHC: 6.28 (+0.03), CGIX: 1.76 (-0.06)
CareDx Presents Validation of AlloSure(R) at AACC Conference Session on Emerging Topics in Laboratory Medicine
GlobeNewswire - Thu Aug 04, 3:58PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, presented on the analytical validation of AlloSure at the 68 American Conference on Clinical Chemistry (AACC) in Philadelphia, PA. The CareDx abstract at AACC was one of 22 selected for an oral presentation from over 800 submitted abstracts.
CDNA: 3.76 (-0.06)
Teladoc (TDOC) Q2 Loss Narrower Than Expected, Gives View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 10:04AM CDT
Teladoc (TDOC) incurred loss in the quarter due to an increase in cost of advertising in its direct-to-consumer segment.
TDOC: 18.64 (-0.31), ABCO: 43.58 (-0.60), CDNA: 3.76 (-0.06), AHS: 33.20 (-1.38)
CareDx Supports FDA Development of Next Generation Sequencing Guidelines, Offers Further Perspective on Clinical Grade Quality and Data
GlobeNewswire - Mon Aug 01, 3:05PM CDT
CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, commends the FDA on the release of two draft guidance documents on the standards and the use of public databases for variant detection for Next Generation Sequencing (NGS). Both documents were further supported through a hosted webinar on July 27.
CDNA: 3.76 (-0.06)
CareDx to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 10, 2016
GlobeNewswire - Mon Aug 01, 3:02PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the second quarter 2016 after the market closes on Wednesday, August 10, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
CDNA: 3.76 (-0.06)
AlloSure(TM) Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
GlobeNewswire - Mon Jun 13, 6:30AM CDT
CareDx at the Forefront of Personalized Medicine in Transplantation
CDNA: 3.76 (-0.06)
CareDx (CDNA) Looks Good: Stock Adds 5.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 7:40AM CDT
CareDx, Inc. (CDNA) saw its shares almost 6% in the last trading session.
AIRM: 32.45 (-0.68), CDNA: 3.76 (-0.06)
CareDx to Host Call to Provide First Analysis of Data from DART Study
GlobeNewswire - Mon Jun 06, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will host a conference call on June 13, 2016 at 4:00 pm ET to provide initial results from the company's DART study.
CDNA: 3.76 (-0.06)
CareDx to Present at 2016 Jefferies Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, CareDx President & Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be presenting and available for meetings at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 4:30pm ET.
CDNA: 3.76 (-0.06)
CareDx and QIAGEN Enter Into Commercial Collaboration to Enhance HLA Lab Experience Using QIAxcel Instrumentation and CareDx HLA Typing Technology
GlobeNewswire - Tue May 31, 7:00AM CDT
CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced it has signed a memorandum of understanding to collaborate with QIAGEN, the leading provider of Sample to Insight solutions for the life sciences and diagnostics industry.
CDNA: 3.76 (-0.06)
CareDx Announces Completion of Enrollment in Multicenter Kidney Transplant Study to Validate Cell-Free DNA Technology
GlobeNewswire - Fri May 27, 3:05PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that the DART study has reached its enrollment goal.
CDNA: 3.76 (-0.06)
CareDx, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Fri May 06, 6:30AM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2016.
CDNA: 3.76 (-0.06)
CareDx to Present Clinical Abstracts Containing New Data at the 2016 ISHLT On AlloMap(R) & AlloSure(TM) in heart transplant patients
GlobeNewswire - Thu Apr 28, 3:52PM CDT
CareDx, Inc. (Nasdaq:CDNA), a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced clinical presentations for the 36 Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) being held April 27 - 30, 2016 in Washington, DC.
CDNA: 3.76 (-0.06)
CareDx to Announce First Quarter 2016 Financial Results and Host Conference Call on May 6, 2016
GlobeNewswire - Tue Apr 26, 3:01PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the first quarter 2016 before the market opens on Friday, May 6, 2016. The Company will host a corresponding conference call beginning at 5:30am PT/8:30am ET.
CDNA: 3.76 (-0.06)
CareDx Completes Allenex Acquisition
GlobeNewswire - Thu Apr 14, 3:15PM CDT
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced the completion of its previously announced acquisition of Allenex AB.
CDNA: 3.76 (-0.06)
CareDx Announces $22 Million Private Placement
GlobeNewswire - Thu Apr 14, 3:14PM CDT
CareDx, Inc. (NASDAQ:CDNA) ("CareDx" or the "Company"
, a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced that it has entered into an agreement to sell approximately 592,000 units in a private placement to be issued by CareDx, for aggregate proceeds in the amount of approximately $14.1 million plus an additional $8 million to be reserved for future investment by certain shareholders. The units were sold to selected institutional and accredited investors and included new shareholders as well as significant participation by current shareholders of CareDx. CDNA: 3.76 (-0.06)
